Outcome | Pre-SIC* | Post-SIC† | Coefficient/OR (95% CI)‡ | P value |
(n=166 admits) | (n=149 admits) | |||
Length of stay, median (IQR), days | 5.5 (3–11) | 5 (3–9) | −1.7 (−3.56 to 0.19)§ | 0.078 |
Discharged on corticosteroids¶ | 121 (75.6%) | 96 (69.1%) | 0.60 (0.33 to 1.10)** | 0.101 |
Use of non-steroidal immunosuppression | 24 (14.5%) | 18 (12.1%) | 0.87 (0.43 to 1.77)** | 0.702 |
ICI discontinuation for irAE†† | 74 (66.1%) | 61 (67.0%) | 1.04 (0.55 to 1.98)** | 0.897 |
Died during irAE admission | 11 (6.6%) | 13 (8.7%) | 1.46 (0.60 to 3.55)** | 0.398 |
IrAE readmission | 43 (25.9) | 22 (14.8) | 0.46 (0.22 to 0.95)‡‡ | 0.036 |
Length of stay of irAE readmission, median (IQR), days | 7 (3–16) | 6 (3–10) | −8.08 (−16.03 to 0.14)§ | 0.046 |
Bold values are statistically significant,
*Data are presented as number (percentage) of admissions, unless otherwise indicated; pre-SIC date range is April 2, 2016–October 2, 2017.
†Data are presented as number (percentage) of admissions, unless otherwise indicated; post-SIC date range is October 3, 2017–October 24, 2018.
‡Data are presented as coefficient (95% CI) for linear regressions (continuous variables) and OR (95% CI) for logistic regressions (categorical variables).
§Multivariable linear regression with covariates: age, sex, irAE confirmation status, malignancy, ICI class and primary toxicity type.
¶Excludes patients with thyroid toxicities or diabetes mellitus (given steroids are not indicated) as the irAE. Pre-SIC n=160; post-SIC n=139.
**Multivariable logistic regression with covariates: age, sex, irAE confirmation status, malignancy, ICI class, primary toxicity type and presence of multiple toxicities.
††Excludes patients with endocrine toxicities (given ICI discontinuation is not indicated) as well as patients who previously discontinued ICI prior to admission or discontinued ICI for any non-irAE reason (disease progression). Pre-SIC n=112; post-SIC n=91.
‡‡Multivariable logistic regression with covariates: age, sex, irAE confirmation status, malignancy, ICI class, primary toxicity type, presence of multiple toxicities and ICI discontinuation for toxicity.
ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; SIC, Severe Immunotherapy Complications.